Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. - Wikidata - awgldk - TriplyDB

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

http://www.wikidata.org/entity/Q37978509

about

Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparti Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.Polylactic Acid-Lemongrass Essential Oil Nanocapsules with Antimicrobial Properties Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.Liposomal formulations for inhalation.Nanoparticle-mediated pulmonary drug delivery: a review Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.Dry powder inhalers in COPD, lung inflammation and pulmonary infections.Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives.Loco-regional administration of nanomedicines for the treatment of lung cancer.Dry powder inhalation: past, present and future.The analysis of pneumatic atomization of Newtonian and non-Newtonian fluids for different medical nebulizers.Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection.Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.Hydroxypropyl methylcellulose-based controlled release dosage by melt extrusion and 3D printing: Structure and drug release correlation.Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research.Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies Phospholipids in pulmonary drug delivery

P2860

Q33858681-E859AD6D-34D2-424E-8BDB-94A235D5D3B1 Q34577430-C6AAFE28-D28D-4A49-86D8-030950515928 Q34583529-7C527DCE-3A5B-4C16-A3EF-3DFF8D2AEE83 Q34660273-6976EBD9-4127-47BF-A60A-E6041ACCAE7E Q36555371-0DC6C64B-AFDC-420C-A9FA-BB9FFBF2FCA2 Q37214386-4BFCCDC2-4855-40C0-901F-2F565561AEA7 Q37290819-386CC089-29B9-49BE-8E5B-7934C9113976 Q37354043-14642508-94F5-4F40-BBDE-A5465D952792 Q38126942-E20E61EE-6EB8-4AD1-9DAB-847F941B960F Q38203377-C3E493F6-3AC6-4496-A7A8-85645FFD30B8 Q38214155-2C6B44EB-D04C-4A4F-8FDB-867C06405DAA Q38267333-D8656BE6-2157-499F-9DC6-415112D45DDB Q38569772-0D75CCC9-D065-4ADE-A52B-0516CB60AB00 Q38639228-8285758A-F02A-4F6F-8AE5-BA4718E2D018 Q38830375-B78D028D-1BB3-48B9-90CE-05D1405C11BA Q40489135-59532360-3A59-4FCC-AE5B-F4A81CF3E1CA Q41907356-B44A7A40-9C31-4966-8E67-A98DABE69B91 Q42961541-18E75FB6-126E-4F5E-B453-AE12529258BD Q47666562-18FD38EE-930D-4A96-875D-1F10B62C007D Q47771876-78DD0D31-685F-4D4E-AB2E-6D13412ABB32 Q57172145-1DCFB6A3-2650-4B64-86C9-112B6A00607A Q59089495-5BE0B22A-A984-41D1-959B-1091E5C7A11D

P2860

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

http://www.wikidata.org/entity/Q37978509

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

@en

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

@nl

type

label

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

@en

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

@nl

prefLabel

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

@en

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

@nl

P1433

Q37978509-90A9D359-1C5D-4C53-A3D4-59CB1F7F33AF

P1476

Q37978509-2C1508A9-DD11-4234-8C1A-158B7CE886B8

P2093

Q37978509-4847B1DC-7225-4B6B-A087-8CA89014B7E4

Q37978509-88E11C63-8E81-4254-9319-85D4A50B0946

Q37978509-B50AD35E-A825-498A-9570-A59B5528006F

P2860

Q37978509-0A1BADE3-1200-40D5-B4AF-0C9FA8F7CE1B

Q37978509-0B20D0BF-01DE-43D7-817E-F4BCF712CF58

Q37978509-0CA55F42-18B2-4B11-896D-6E880152733C

Q37978509-11E861E0-117A-4741-98A6-0125CEE42F20

Q37978509-1ACFFF56-1347-4CBB-BBE1-B1C5487AF024

Q37978509-1C0853D6-D9DF-4001-9EEA-4BFAC5204FB7

Q37978509-1C9E88E9-6B8C-4155-BAB2-0EC8C3D9EC20

Q37978509-1EEFA0D8-6E2B-4E82-AB65-A449AF7C856F

Q37978509-2059A960-BF74-4228-B211-03E24A5D4886

Q37978509-224D0BC2-5742-491E-9907-FBED8E1278C3

P2888

Q37978509-548AE09E-AE30-4E11-8B08-A1ECF7AA437C

P304

Q37978509-18BB06D2-63D5-4932-BD0E-E0E8622CB4DA

P31

Q37978509-A9B127D9-A047-4CA4-B1A1-394A97A3F086

P356

Q37978509-3450845E-1DAE-4BC9-B81F-52336FFA4C29

P433

Q37978509-D987245A-A3A8-49B0-B71D-AE7F373933F9

P478

Q37978509-F18C2E68-F5AA-474D-83A4-C8017018E879

P577

Q37978509-4D0BCB4E-3885-4B97-BEAB-3F321EA1F395

P698

Q37978509-403B4C38-B55B-4637-8904-55B9652B8D7D

P356

S00408-011-9360-X

P1433

P1476

Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

@en

P2093

Don Hayes

http://www.w3.org/2001/XMLSchema#string

Heidi M Mansour

http://www.w3.org/2001/XMLSchema#string

Lauren Willis

http://www.w3.org/2001/XMLSchema#string

P2860

Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug

Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.

Inhalable microparticles containing large payload of anti-tuberculosis drugs.

Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial.

Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Liposomal aerosols in the management of pulmonary infections.

Nanomedicine in pulmonary delivery

Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.

Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.

P2888

s00408-011-9360-x

P304

251-262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00408-011-9360-X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

190

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22274758

http://www.w3.org/2001/XMLSchema#string